Search

U.S. FDA Approves Once-daily Jentadueto® XR (linagliptin and metformin hydrochloride extended-release) Tablets for Adults with Type 2 Diabetes

A day of giving back at Pegasus Therapeutic Riding

Take a look at our volunteer day spent refreshing a farm committed to equine therapy.

Efficacy and safety maintained in patients who switched from Humira® to biosimilar Cyltezo®

New Long-Term Data Published in Circulation Reinforce Safety Profile of Pradaxa® (dabigatran etexilate mesylate)

US FDA grants Fast Track designation to Jardiance® (empagliflozin) to improve outcomes following a heart attack

A legacy in the making: Working together to spark meaningful change

Discover Jim’s passion for being an advocate for meaningful causes.

Bringing focus to unmet needs in biliary tract and pancreatic cancer with the Brightline-2 Trial

Brightline-2 clinical trial is studying our investigational MDM2-p53 antagonist for people with advanced cancer in the biliary tract or pancreatic cancer.

FDA grants Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease

Protein Degraders: Changing the Game in Cancer Drug Discovery

Results from the INJOURNEY™ trial investigating Ofev® with add-on pirfenidone provide new insights into this combination treatment for IPF

Real-world analysis reinforces that Gilotrif® dose adjustments reduce the frequency and intensity of adverse drug reactions without impacting efficacy

dose adjustments reduce the frequency and intensity of adverse

FDA Approves Stiolto® Respimat® sNDA to Add Data on COPD | BI US

FDA approves labeling for Stiolto® Respimat® (tiotropium bromide & olodaterol) with data showing reduction in COPD exacerbations. View ISI, PI & Med Guide.

Jardiance® (empagliflozin) to be studied for the treatment of people with chronic heart failure

Jardiance® (empagliflozin) analysis reinforces established safety profile

U.S. FDA approves Synjardy® XR (empagliflozin/metformin hydrochloride extended-release) tablets for adults with type 2 diabetes

First-in-class type 2 diabetes treatment Glyxambi® (empagliflozin/linagliptin) tablets for adults now available in U.S. pharmacies

Initial results from EMPRISE real-world evidence study show Jardiance® was associated with reduced risk for hospitalization for heart failure compared with DPP-4 inhibitors in people with type 2 diabetes with and without cardiovascular disease

Initial results from EMPRISE real-world evidence study show Jardiance® was associated with reduced risk for hospitalization for heart failure compared with DPP-4 inhibitors in people with type 2 diabetes with and without cardiovascular disease

U.S. FDA Accepts New Drug Application for Triple Combination Tablet for Adults with Type 2 Diabetes

Employees compassionately help local communities with country-wide food drive

Coming together to bring food to people in need

U.S. FDA Grants Breakthrough Therapy Designation for Spesolimab for the Prevention of Flares in Adults with Generalized Pustular Psoriasis (GPP)

Consumer Health Data Privacy Statement

This Consumer Health Data Privacy Statement applies to “Consumer Health Data,” as that term has been defined under applicable law.

U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure

Jardiance® reduced risk of cardiovascular death in adults with type 2 diabetes and peripheral artery disease

Jardiance® reduced risk of kidney disease progression in adults with type 2 diabetes and established cardiovascular (CV) disease independent of control of conventional CV risk factors

Click here to read more about how the use of JARDIANCE reduced the risk of kidney disease progression in adults with established CVD and T2D.

New analysis estimates the positive impact of Jardiance® on life expectancy in adults with type 2 diabetes and established cardiovascular disease

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers

Search

U.S. FDA Approves Once-daily Jentadueto® XR (linagliptin and metformin hydrochloride extended-release) Tablets for Adults with Type 2 Diabetes

A day of giving back at Pegasus Therapeutic Riding

Efficacy and safety maintained in patients who switched from Humira® to biosimilar Cyltezo®

New Long-Term Data Published in Circulation Reinforce Safety Profile of Pradaxa® (dabigatran etexilate mesylate)

US FDA grants Fast Track designation to Jardiance® (empagliflozin) to improve outcomes following a heart attack

A legacy in the making: Working together to spark meaningful change

Bringing focus to unmet needs in biliary tract and pancreatic cancer with the Brightline-2 Trial

FDA grants Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease

Protein Degraders: Changing the Game in Cancer Drug Discovery

Results from the INJOURNEY™ trial investigating Ofev® with add-on pirfenidone provide new insights into this combination treatment for IPF

Real-world analysis reinforces that Gilotrif® dose adjustments reduce the frequency and intensity of adverse drug reactions without impacting efficacy

FDA Approves Stiolto® Respimat® sNDA to Add Data on COPD | BI US

Jardiance® (empagliflozin) to be studied for the treatment of people with chronic heart failure

Jardiance® (empagliflozin) analysis reinforces established safety profile

U.S. FDA approves Synjardy® XR (empagliflozin/metformin hydrochloride extended-release) tablets for adults with type 2 diabetes

First-in-class type 2 diabetes treatment Glyxambi® (empagliflozin/linagliptin) tablets for adults now available in U.S. pharmacies

Initial results from EMPRISE real-world evidence study show Jardiance® was associated with reduced risk for hospitalization for heart failure compared with DPP-4 inhibitors in people with type 2 diabetes with and without cardiovascular disease

U.S. FDA Accepts New Drug Application for Triple Combination Tablet for Adults with Type 2 Diabetes

Employees compassionately help local communities with country-wide food drive

U.S. FDA Grants Breakthrough Therapy Designation for Spesolimab for the Prevention of Flares in Adults with Generalized Pustular Psoriasis (GPP)

Consumer Health Data Privacy Statement

U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure

Jardiance® reduced risk of cardiovascular death in adults with type 2 diabetes and peripheral artery disease

Jardiance® reduced risk of kidney disease progression in adults with type 2 diabetes and established cardiovascular (CV) disease independent of control of conventional CV risk factors

New analysis estimates the positive impact of Jardiance® on life expectancy in adults with type 2 diabetes and established cardiovascular disease